The committee provided advice on 3 submissions, including:
Extension of indication for VAXNEUVANCE, containing Pneumococcal purified capsular polysaccharides, for active immunisation and prevention of pneumococcal disease (sponsor Merck Sharp & Dohme (Australia) Pty Ltd)
Provisional registration of new vaccine SPIKEVAX BIVALENT ORIGINAL / OMICRON BA.4-5 COVID-19 vaccine, containing elasomeran and davesomeran (sponsor Moderna Australia Pty Ltd).
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.